ArticleOncology letters2026
Malignant mesothelioma of the tunica vaginalis testis: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy of Nivolumab in Chemotherapy-Resistant Mesothelioma of the Tunica Vaginalis Testis: A Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- Malignant mesothelioma of the tunica vaginalis testis initially misdiagnosed as a benign testicular hydrocele: a case report.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant mesothelioma of the tunica vaginalis testis (MMTVT) is a rare pathological entity. The present report describes the case of a patient who presented with insidious-onset right lower abdominal pain and was diagnosed via histopathological examination following a radical right orchidectomy. After 7 months, the patient developed a palpable mass along the spermatic cord, which prompted a laparoscopic retroperitoneal lymph node dissection combined with an inguinal tumor resection. Adjuvant chemotherapy with pemetrexed and cisplatin was administered thereafter. At 9 months after the initial surgery, a groin mass was surgically excised, with pathology revealing fibroinflammatory changes. The patient remained under close surveillance without evidence of recurrence. Radiation therapy was initiated at 13 months post-surgery but was temporarily discontinued due to adverse effects. Given the current absence of standardized treatment guidelines for MMTVT, radical surgical resection combined with adjuvant radiotherapy or chemotherapy remains the mainstay of therapy, with the inguinal approach being the most commonly employed technique. Given the validated efficacy of immunotherapy in certain rare diseases and pleural mesothelioma, it may represent a promising therapeutic alternative for MMTVT patients whose pathological immunohistochemistry meets eligibility criteria and who have failed standard adjuvant radiotherapy and chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.